Qorvo’s sensor-based technology immunoassay platform selected by expert committee for development grant.
The Foundation for Innovative New Diagnostics (FIND) announced awards to support the development, manufacture and feasibility testing for two prototype hepatitis C virus (HCV) core antigen (cAg) immunoassays for diagnosis at point-of-care.
Zomedica’s latest diagnostic collaborator, Qorvo Biotechnologies, LLC (Qorvo) is one of the companies to receive support to develop and test the feasibility of a cartridge-based assay using their proprietary investigational Bulk Acoustic Wave (BAW) platform technology.
This is the same sensor-based technology that enables Zomedica’s ZM-024 point-of-care diagnostic platform that is being developed with the aim to provide clinical veterinarians with a collection of rapid reference-lab quality tests at the point-of-care.
FIND is a global non-profit organization that awards grants to organizations with innovative technologies and partners with industry leaders such as Abbott, BD (Becton Dickinson), and Chembio to develop diagnostics that combat major diseases affecting low- and middle-income countries.
Grant applications are competitive and are evaluated by a committee comprised of FIND senior management and external subject matter experts. The core criteria evaluated for each application include potential:
- Probability of success
“The fact that a prestigious, global organization like FIND selected Qorvo as a diagnostic partner is a testament to the platform’s potential performance capabilities,” stated Stephanie Morley, DVM, Chief Operating Officer and Vice President of Product Development at Zomedica. “We’re excited to translate this same BAW sensor technology as a potential point-of-care diagnostic solution for clinical veterinarians.”
Qorvo’s BAW diagnostic platform and ZM-024 are investigational devices, are not currently available for sale, and are limited to investigational use only.
For more information about the FIND awards, click here.
News In Brief:
- FIND is a global non-profit that drives innovation in the development and delivery of diagnostics to combat major diseases affecting the world’s poorest populations.
- Qorvo to receive FIND grant to test the feasibility of cartridge-based immunoassay for detection of hepatitis C virus (HCV) with the aim to provide rapid diagnostic tests at the point of care.
- The competitive and rigorous grant application process takes approximately five (5) months for review and evaluation of technologies by expert FIND committee.
- FIND technology evaluation criteria includes potential for affordability, performance, usability, and probability of success—which are all ideal when translating technology to veterinary medicine.
Based in Ann Arbor, Michigan, Zomedica (NYSE American:ZOM) (TSX-V:ZOM) is a veterinary diagnostic and pharmaceutical and company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. Zomedica’s product portfolio will include novel diagnostics and innovative therapeutics that emphasize patient health and practice health. With a team that includes clinical veterinary professionals, it is Zomedica’s mission to give veterinarians the opportunity to lower costs, increase productivity and grow revenue while better serving the animals in their care. For more information, visit www.ZOMEDICA.com.
- Email Alerts: http://investors.zomedica.wpengine.com
- LinkedIn: https://www.linkedin.com/company/zomedica
- Facebook: https://www.facebook.com/zomedica/
- Twitter: https://twitter.com/zomedica